Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Liquidia CorpLQDA · Entity 1860 | CMO and Head of R&D | January 16, 2022 | January 19, 2022 |
| Liquidia Technologies IncLQDA · Entity 145051 | Chief Medical Oficer | May 18, 2020 | May 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Liquidia Corp
Report date January 16, 2022 · Filed January 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,000 |
Reported balance
After 2022-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-16 · Grant · Acquired 35,000 · Balance 35,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2032-01-16 | Direct | 70,000 |
Reported balance
After 2022-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-16 · Grant · Acquired 70,000 · Balance 70,000 F3: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter.
F3: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter.
Liquidia Technologies Inc
Report date May 18, 2020 · Filed May 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2030-05-18 | Direct | 230,000 |
Reported balance
After 2020-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-18 · Grant · Acquired 230,000 · Balance 230,000 F1: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on May 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on May 18, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2022 Filed Jan 19, 2022 16:36 UTC | Liquidia Corp LQDA · Entity 1860 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001104659-22-005473 · tm221559-6_4seq1.xml · derivative · entry 2 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-01-16 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 16:36 UTC | Liquidia Corp LQDA · Entity 1860 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005473 · tm221559-6_4seq1.xml · derivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F2 · derivative.expiration_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 21:03 UTC | Liquidia Corp LQDA · Entity 1860 | Tax withholdingCommon Stock | 11,882 | $4.90 | $58,203.98 |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · nonDerivative · entry 3 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,881 Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 21:03 UTC | Liquidia Corp LQDA · Entity 1860 | Tax withholdingCommon Stock | 487 | $5.05 | $2,456.92 |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · nonDerivative · entry 2 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,763 Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:03 UTC | Liquidia Corp LQDA · Entity 1860 | GrantPerformance Stock Units · Derivative | 51,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · derivative · entry 4 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,250 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. F2 · derivative.exercise_date: On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. F2 · derivative.expiration_date: On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:03 UTC | Liquidia Corp LQDA · Entity 1860 | Exercise / conversionCommon Stock | 51,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · nonDerivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 18:15 UTC | Liquidia Corp LQDA · Entity 1860 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095512 · tm2123135-7_4seq1.xml · derivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 20:19 UTC | Liquidia Corp LQDA · Entity 1860 | GrantPerformance Stock Units · Derivative | 51,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-005981 · tm213622-1_4seq1.xml · derivative · entry 2 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,250 Underlying: Common Stock · 51,250 shares Expires not disclosed F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 20:19 UTC | Liquidia Corp LQDA · Entity 1860 | GrantEmployee Stock Option (right to buy) · Derivative | 102,500 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-21-005981 · tm213622-1_4seq1.xml · derivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 Underlying: Common Stock · 102,500 shares Expires 2031-01-19 F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025. Read SEC document |
| May 18, 2020 Filed May 19, 2020 16:40 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001104659-20-063810 · a4.xml · derivative · entry 1 Shah Tushar · CIK 0001487632 · Chief Medical Oficer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2030-05-18 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on May 18, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.